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Drug-related pityriasis rubra pilaris with acantholysis
Pityriasis rubra pilaris sa akantalizom izazvana lekom
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Abstract
Introduction. Acantholysis is rarely reported histological
feature of Pityriasis rubra pilaris (PRP), recently recognized
as having diagnostic specificity for differentiating PRP from
psoriasis. Case report. Adult male patient one week after
the introduction of simvastatin had experienced pruritic
erythemo-squamous eruption on head and upper trunk that
in a month progressed to erythrodermia, with islands of
sparing. Histological picture combined pemphigus-like ac-
antholysis with alternating hyper- and parakeratosis, follicu-
lar plugs and dermal inflammation, and confirmed the clini-
cal diagnosis of classic adult type 1 PRP. Acitretin therapy
resulted in a resolution of skin disease. Patch test with sim-
vastatin was negative, scratch test was positive, and it was
estimated that potential risk of oral challenge with simvas-
tatin outweighed actual need for it. Drug triggering PRP
episode is the most likely explanation for temporal relation
between the start of simvastatin treatment and skin erup-
tion.  Conclusion. In management of rare inflammatory
skin disease, such as PRP, we have to carefully observe and
evaluate not only diagnostic features but possible external
influences on its course also.
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Apstrakt
Uvod. Akantoliza je retko prikazivana histološka karakteri-
stika Pityriasis rubra pilaris (PRP) ÿiji znaÿaj u diferencijalnoj
dijagnozi prema psorijazi je nedavno prepoznat. Prikaz
bolesnika. Prikazali smo odraslog bolesnika sa eritemos-
kvamoznom erupcijom po glavi i gornjem delu trupa praýe-
nom svrabom koji je poÿeo nedelju dana nakon uvoĀenja
simvastatina. Tokom mesec dana razvila se eritrodermija sa
ostrvcima pošteĀene kože. Histološki nalaz suprabazalne
akantolize sa naizmeniÿnim zonama hiperkeratoze i parake-
ratoze u epidermisu i inflamatornog infiltrata u dermisu
potvrdio je kliniÿku dijagnozu klasiÿnog adultnog oblika
PRP. Terapija acitretinom dovela je do izleÿenja kožnih
promena. Epikutani patch test sa simvastatinom bio je nega-
tivan, scratch test bio je pozitivan, a test ekspozicije nije ura-
Āen jer je procenjeno da u tom momentu nosi veliki rizik.
Epizoda PRP pokrenuta lekom je najverovatnije objašnjenje
za vremensku povezanost kožnih promena sa poÿetkom
uzimanja simvastatina. Zakljuÿak. U leÿenju retkih zapa-
ljenskih oboljenja kože treba pažljivo da tumaÿimo znaÿaj
kako dijagnostiÿkih parametara, tako i moguýih spoljašnjih
uticaja na tok oboljenja.
Kljuÿne reÿi:
pitirijazis rubra pilaris; simvastatin; dijagnoza; leÿenje
lekovima; leÿenje ishod.
Introduction
Pityriasis rubra pilaris (PRP) is a rare inflammatory
skin disease, with 6 distinct forms that differ in the age of
onset, clinical features, behavior, and prognosis: adult-onset
forms (classical and atypical), juvenile forms (classic, cir-
cumscribed and atypical), and human immunodeficiency vi-
rus-associated one. Pathogenesis, etiology and triggering
factors of PRP are not well characterized, and dilemmas
about the diagnosis, associated diseases or therapeutic ap-
proach are frequent. Psoriasis is one of the most important
differential diagnostic considerations, more in clinical than
histological aspects. Acantholysis is a rarely reported his-
tological feature of PRP that is recently recognized to have
diagnostic specificity for differentiating PRP from psoriasis.
Case report
A 61-year-old male patient, experienced pruritic ery-
thematous scaling eruption on head and upper trunk one
week after the introduction of simvastatin 10 mg daily (Sim-
vor
® tbl 10 mg, Ranbaxy lab). The patient had discontinued
simvastatin in five days, pruritus subsided, but during the
next month the eruption spread to erythrodermia with pal-Strana 872 VOJNOSANITETSKI PREGLED Volumen 70, Broj 9
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moplantar keratoderma, eyelid ectropion and small sharply
demarcated “islands of sparing” (Figure 1). The clinical di-
agnosis was classical adult PRP type 1. The past medical
history of the patient was unremarkable: the patient did not
currently use other medication, nor had reported any previ-
ous drug reaction. Apart from moderate hyperlipidemia, all
the findings were within normal limits, including tempera-
ture, blood count and basic biochemistry profile, tests of thy-
roid function, autoimmune disorders, muscle enzymes, ma-
lignancy screening and direct skin immunofluorescence. Su-
prabasilar acantholysis suggestive for pemphigus vulgaris
was the most prominent histological pattern in biopsy of re-
cent papula (Figure 2), and features more usual for PRP (al-
ternating hyper- and parakeratosis, dyskeratosis, follicular
plugs, perivascular inflammation in upper dermis) were pres-
ent in the biopsy of older plaque (Figure 3). Methylprednis-
olone therapy (initially 80 mg daily, tapered during 4 weeks)
was without response. Acitretin, 35 mg daily brought a com-
plete clearance in 3 months, following an inverse pattern of
the initial cranio-caudal spread. It was discontinued after five
months, without recurrence of PRP for the next 4 years. Nine
months after clearance skin tests were performed with 2%
simvastatin solution in water for injection; patch test was
negative, scratch skin test was positive, revealed wheal along
scratch line through simvastatin solution (Figure 4). Oral ex-
position test was not performed because it was estimated that
a potential risk outweighed the actual need for simvastatin.
Fig. 3 – Skin histology: alternating hyper- and
parakeratosis, dyskeratosis (haematoxylin-eosin, original
magnification u 200).
Fig. 4 – Positive scratch skin test with simvastatin: the upper
line is a 3 mm wide wheal along the scratch line with
aqueous simvastatin solution; the lower scratch line,
surrounded with flare, represents negative control with
water for injection.
Discussion
There is no single histological characteristic unique for
PRP. The diagnosis combines several features (alternating
hyper- and parakeratosis, follicular plugs, follicular lip para-
keratosis, dermal perivascular infiltrate) and exclusion of
Fig. 1 – Erythrodermia with sharply demarcated islands of
unaffected skin, typical adult form of Pityriasys rubra
pilaris (PRP).
Fig. 2 – Skin histology: suprabasal acantholysis suggestive
of pemphigus vulgaris (haematoxylin-eosin, original
magnification u 200).Volumen 70, Broj 9 VOJNOSANITETSKI PREGLED Strana 873
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other differentials 
1. Early reports about acantholysis in PRP
histology treated it as rare or incident finding 
2, 3. One large
retrospective analysis of PRP histology detected small foci of
acantholysis in about 70% of specimens 
1. Types of epider-
mal clefts in PRP were described as Darier-like, Hailey-
Hailey-like, pemphigus-like, visible as solitary or combined
patterns, or having features of epidermolytic hyperkeratosis 
1–4.
With hypergranulosis and follicular plugs, acantholysis was of
help in distinguishing histological findings favouring PRP to-
wards others that are more psoriatic (capillary dilatations, hy-
pogranulosis and epidermal pustules) 
1. Although the term
acantholytic PRP was proposed for cases clinically and his-
tologically suggestive of blistering disease, further reports of
cases or case series are sparse and acantholysis is still a fre-
quent cause of diagnostic dilemma 
5. All reported acantholytic
PRP cases were typical adult erythrodermic form (type 1
PRP), but it is not conclusive whether acantholysis is a feature
of solely type 1, or this form allows easier clinical recognition
in spite of the unusual histology 
1–5.
Intriguing is a relation between the start of new drug use
and particular PRP episode, especially role of immediate hy-
persensitivity to simvastatin (as suggested by positive cutane-
ous scratch test), but can only be hypothesized. Oral challenge
is the only way to sufficiently prove causal role of simvastatin,
but due to severity of erythrodermia and positive skin tests, the
risk of oral challenge was estimated to be unacceptable.
Scratch test, when positive, is confirmatory test for immediate
type hypersensitivity (urticaria – anaphylaxis), and presented
case of PRP had no elements of such reaction pattern. Patch
skin test when positive is confirmatory test for delayed type
hypersensitivity (i.e. drug induced exanthemata), but patch test
with simvastatin was negative in the presented patient, there-
fore excluding drug eruption with features of PRP. Drug trig-
gering PRP is the most likely explanation for temporal asso-
ciation between the introduction of drug and occurrence of
skin eruption, and quite long period of several months for
clearance of PRP after drug discontinuation.
Pathogenesis of PRP is not resolved: apart from post-
infectious forms of mostly juvenile and HIV-associated PRP,
triggering events are not characterized also. Drug treatment
as a trigger of PRP has only exceptionally rarely been evalu-
ated. In the literature, one unique case of PRP induced with
labetalol had been confirmed with oral challenge 
6. In the
same period of the seventies of the 20th century beta block-
ers were recognized as triggers of psoriasis, skin disease that
share some similarities with PRP. Later on drug-related PRP
was hypothesized in few cases in the retrospective analysis,
but were not evaluated by appropriate challenges in particu-
lar patients; incriminated drugs were anticonvulsants, anti-
histamines, diltiazem 
1. Aggravation of PRP has been de-
scribed with topical imiquimod, suggesting that an imiqui-
mod induced shift towards Th1 cytokine profile could be
proinflammatory stimulus for PRP 
7. Statins have numerous
pleiotropic (cholesterol-independent) effects on the immune
system, and in clinical setting statins exert both anti- and
proinflammatory properties. Cases of autoimmune diseases
(lupus, dermatomyositis) closely related to statin treatments
were described in the literature 
8. Also, cases of acquired
ichtyosis caused by pravastatin treatment 
9, or psoriasis re-
lapsing upon treatment with different statins 
10 suggest that
statin effects on epidermal lipid homeostasis can have clini-
cal implications in predisposed individuals.
Conclusion
Acantholysis is unexpected and underreported his-
tological finding that should be recognized in diagnostic
management of PRP. We should be careful to observe and to
further investigate possible external influences on the entire
course of rare inflammatory diseases, such as PRP. More
extensive knowledge about the pathogenesis sequence of
PRP is needed, to be able to estimate the role of external
factors possibly influencing a cascade of skin inflammation
and the course of PRP.
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